BDBlandine Dozières-Puyravel

Blandine Dozières-Puyravel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Blandine Dozières-Puyravel has a total of 97 co-authors. Here are the top co-authors by number of shared publications:

  • Stéphane Auvin

    Assistance Publique‐Hôpitaux de Paris, Pediatric Neurology Department, Reference Center for Rare Epilepsies, Member of European Reference Network EpiCARE Hôpital Universitaire Robert Debré Paris France

    15 shared publications
  • Hala Nasser

    Institut Hospitalo‐Universitaire Robert‐Debré du Cerveau de l'Enfant Paris France

    3 shared publications
  • Luigi Titomanlio

    Pediatric Emergency Department Assistance Publique ‐ Hôpitaux de Paris, Robert Debré University Hospital Paris France

    3 shared publications
  • Anna Loussouarn

    APHP-Sorbonne Université, Département de Génétique, Groupe Hospitalier Pitié-Salpêtrière and Hôpital Armand Trousseau, Paris, France

    2 shared publications
  • François-Xavier Mauvais

    Université Paris Cité, Inserm, UMR1141, NeuroDiderot

    2 shared publications
  • Johan Personnic

    APHP. Service de Neurologie Pédiatrique, Hôpital Robert-Debré, Paris, France; APHP, Service de Pédiatrique, Hôpital Ambroise-Paré, France; APHP. Service des urgences pédiatriques, Hôpital Robert-Debré, Paris, France

    2 shared publications

Latest Publications

  • Open Access

    Multimodal modeling of the ictal onset zone in refractory insular epilepsy and seizure outcome of magnetic resonance‐guided laser interstitial therapy: A pediatric single‐center retrospective study

    by Lelio Guida, Emma Losito, Sebastian Rodrigo, Catherine Chiron, Ludovic Fillon, Marie Bourgeois, Anna Kaminska, Johan Pallud, Nicole Chemaly, Volodia Dangouloff‐Ross, et al.

    Objective: This study was undertaken to evaluate seizure outcomes after magnetic resonance‐guided laser interstitial thermal therapy (MRgLITT) in children with insular epilepsy and to assess how the extent of ablation overlaps with multimodal definitions of the ictal onset zone (IOZ). Methods: We conducted a retrospective, single‐center study including consecutive pediatric patients treated with MRgLITT for insular epilepsy. All patients underwent presurgical evaluation including electroencephalography (EEG) and magnetic resonance imaging (MRI); fluorodeoxyglucose positron emission tomography (FDG‐PET) and stereo‐EEG (SEEG) were performed in negative‐MRI cases. Epileptic zone was identified by visual analysis of SEEG recording. Postablation contrast‐enhancing volumes were manually segmented and coregistered with IOZ estimates derived from Multi‐centre Epilepsy Lesion Detection (MELD) MRI analysis, FDG‐PET voxel‐based analysis, and the Epileptogenicity Index, when available. Spatial concordance between modalities was assessed using Dice similarity coefficients, and the proportion of each IOZ modality encompassed within the ablation volume was correlated with postoperative seizure outcomes (International League Against Epilepsy classification). Results: Eight children (median age = 10.4 years, range = 2.3–17) were included, with a median postoperative follow‐up of 38 months. Two patients had insular tumors, and both achieved seizure freedom after complete ablation. Among the six MRI‐negative patients, FDG‐PET revealed insular hypometabolism in four, MELD detected a median of one insular cluster (range 1–3), and SEEG identified focal insular ictal activity in three cases. Overall, four negative‐MRI patients achieved seizure freedom: three after MRgLITT alone and one after MRgLITT combined with frontal opercular resection. One transient postoperative aphasia was observed. Intermodality spatial concordance was low across all comparisons. A greater proportion of FDG‐PET hypometabolism included in the ablation volume was associated with better seizure outcomes ( p = .012). Significance: MRgLITT is an effective and safe treatment option for focal insular epilepsy in children, either as standalone therapy or in a combined approach. Optimal outcome depends on accurate preoperative delineation of the IOZ and its complete ablation.

  • Open Access

    Weaning from ketogenic diet therapy in children with epilepsy: Insights from a retrospective study

    by Noémie Donnard, Blandine Dozières‐Puyravel, Katia Geraldes, Céline Perrot, Virginie Quéméner, Estelle Goujon, Pierre Truchy, Hala Nasser, François‐Xavier Mauvais, Marion Danse, et al.

    Objective: This study was undertaken to describe weaning practices following ketogenic diet therapy (KDT) in children with epilepsy and to identify clinical factors associated with seizure exacerbation or antiseizure medication adjustments during or after weaning from KDT. Methods: This retrospective observational study examined patients who initiated and discontinued KDT between 2016 and 2022 at a tertiary epilepsy center. Patients with GLUT1 deficiency, ongoing KDT, or less than 1 year of follow‐up postdiscontinuation were excluded. Clinical, electroencephalographic (EEG), magnetic resonance imaging, KDT response, weaning duration, and seizure outcomes were analyzed. Responders were defined by ≥50% seizure reduction. Seizure worsening and/or antiseizure medication (ASM) adjustments during weaning were the primary outcomes. Results: Among 57 evaluable patients, 49% were responders and 25% became seizure‐free. During weaning, 62% experienced seizure exacerbation or required ASM modifications. Unfavorable outcomes were significantly associated with shorter KDT duration, shorter weaning periods, higher ASM burden, and abnormal preweaning EEG. Among responders, seizure worsening was not significantly linked to weaning speed alone. At 1 year, seizure freedom was more common in patients who did not experience any issue during the weaning (65% vs. 30%, p = .009). Significance: Our findings underscore the importance of individualized KDT discontinuation plans based on efficacy, EEG activity, and ASM burden. Although prolonged weaning was more common in responders, weaning duration alone did not predict outcomes. These results highlight the need for prospective studies to define optimal weaning strategies for KDT.

  • Open Access

    Assessing the diagnostic performance of investigations in pediatric myoclonic epilepsies: A retrospective cohort study

    by Sophie Brulé, Blandine Dozières‐Puyravel, Hala Nasser, Monique Elmaleh‐Bergès, François‐Xavier Mauvais, Stéphane Auvin

    Objective: The primary purpose was to assess the diagnostic performance of investigations in children with myoclonic epilepsy. The secondary objectives were to examine the definitive syndromic diagnoses and report the outcomes of pediatric myoclonic epilepsies. Methods: We conducted a retrospective monocentric study from a pediatric center for rare epilepsies. We included pediatric patients investigated for myoclonic epilepsy at our center from 2009 to 2022. Data were collected from their medical records. Results: Forty‐one children were included; 32 (78%) underwent untargeted etiological investigations, including brain magnetic resonance imaging and diverse laboratory tests to rule out an underlying etiology for progressive myoclonus epilepsy (PME). These investigations led to an etiological diagnosis of epilepsy for two patients, exclusively based on genetic investigations. At the final follow‐up, an underlying etiology for epilepsy was established for nine patients (22%). The definitive syndromic diagnoses were diverse, comprising myoclonic epilepsy in infancy, epilepsy with myoclonic absences, Rasmussen syndrome, and PME. Some patients were diagnosed with nonsyndromic developmental and epileptic encephalopathy or unclassified nonsyndromic myoclonic epilepsy. Developmental delay or regression at the initial evaluation was found to be significantly associated with an unfavorable neurological outcome, the total number of antiseizure medications (ASMs) prescribed, and the unlikelihood of achieving ASM freedom. No patients with an abnormal head circumference or born of a consanguineous union were in the favorable neurological outcome group, although this finding did not reach statistical significance. Significance: Except for the need to promptly identify diseases for which precision medicine treatments are available, a first‐line genetic approach seems reasonable to investigate children diagnosed with epileptic myoclonus.


  • Open Access

    A second RUBCN variant associated with epileptic encephalopathy and neurodevelopmental delay

    by Lodin‐Pasquier Magalie, Capri Yline, Patat Olivier, Dozières‐Puyravel Blandine, Couque Nathalie

    The RUBCN gene encodes a widely expressed protein called Rubicon, the main function of which is to negatively regulate macroautophagy. A single homozygous pathogenic variant of the RUBCN gene has been reported to date in two unrelated consanguineous Saudi families with spinocerebellar ataxia autosomal recessive 15 (OMIM#613516). This variant is responsible for the deletion of the highly conserved Rubicon Homology (RH) domain, which is important for the colocalization of Rubicon with Rab7 in the late endosome. In this work, we describe a female patient with childhood‐onset epileptic encephalopathy and neurodevelopmental delay carrying a novel homozygous variant in RUBCN (NM_014687.3: c.2126 + 1G>A). A functional study of the RNA revealed that this variant completely abolishes the consensus donor site at the exon 14/intron 14 junction, resulting in the absence of expression of the reference transcript. Two alternative transcripts were expressed: a major transcript resulting from activation of an alternative exonic splice site and a minor transcript with skipping of exon 14. The two alternative transcripts lead to a shift in the reading frame introducing a premature stop codon. The resulting truncated protein lacks the RH domain, which may lead to defective endosomal trafficking as previously described. To our best knowledge, this is the first report of an impairment of RUBCN caused by a splice variant.


  • Pharmacological management of prolonged seizures in Dravet syndrome including intravenous phenytoin

    by Rana Abi Tayeh, Blandine Dozières‐Puyravel, Lionel Arnaud, Luigi Titomanlio, Stéphane Dauger, Sophie Höhn, Eric Le Guern, Stéphane Auvin

    Dravet syndrome (DS) is an infantile onset developmental and epileptic encephalopathy. Sodium channel blockers are known to exacerbate seizures in this syndrome. Due to its high incidence, the management of prolonged seizures is crucial for DS patients. There is still ambiguity regarding the use of intravenous phenytoin for prolonged seizure in DS patients mainly due to the lack of data, raising concern about the safety of it use. We conducted a retrospective study (from January 2009 to January 2020) aiming to assess the management of prolonged seizures in DS with a focus on the use of intravenous phenytoin. Data were collected for patients admitted to our hospital for seizures lasting >5 min. Among 52 identified patients in our database, 23 experienced 59 prolonged seizures managed in our hospital. Only four seizures ceased without rescue medication. Notably, the use of intravenous phenytoin was not associated with discernible adverse effects and was effective in stopping status epilepticus in 71% of cases. This study suggests the safety and efficacy of intravenous phenytoin for prolonged seizure in DS. There is a need for broader investigations of emergency treatments for evidence‐based recommendations for the emergency plan of each patient.


  • PACS2 pathogenic variant associated with malformation of cortical development and epilepsy

    by Rayann Checri, Blandine Dozières‐Puyravel, Monique Elmaleh‐Bergès, Alain Verloes, Stéphane Auvin

    PACS2 pathogenic variants are associated with an autosomal dominant syndrome (OMIM DEE66), associating developmental and epileptic encephalopathy, facial dysmorphism, and cerebellar dysgenesis. However, no malformation of cortical development has been reported yet. We report here a seven‐year‐old child with a history of infantile epileptic spasm syndrome and a right insular polymicrogyria and pachygyria due to de novo PACS2 recurrent mutation c.625G>A (p.Glu209Lys). Our observation raises the question of the role of PACS2 in the cortical development. It also reminds the importance of cerebellar anomalies in the recognition of PACS‐related DEE.


  • Real-life data comparing the efficacy of vigabatrin and oral steroids given sequentially or combined for infantile epileptic spasms syndrome

    by Blandine Dozieres-Puyravel, Hala Nasser, François-Xavier Mauvais, Anne De Saint Martin, Caroline Perriard, Chloé Di Meglio, Claude Cances, Caroline Hachon-Le Camus, Mathieu Milh, Stéphane Auvin


  • Neuropathology findings in KCNQ2 neonatal epileptic encephalopathy.

    by Ludovic Legros, Homa Adle-Biassette, Blandine Dozières-Puyravel, Suonavy Khung, Monique Elmaleh-Bergès, Gaëtan Lesca, Catherine Delanoë, Valérie Biran, Stéphane Auvin